We are live on ! Find out more
FNCH

Finch Therapeutics Group, Inc. Common Stock
FNCH

Delisted

FNCH was delisted on the 24th of May, 2024.

Back to rankings

40 hedge funds and large institutions have $4.6M invested in Finch Therapeutics Group, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less funds holding

Funds holding: 43 → 40 (-3)

44% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 9

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

73% less capital invested

Capital invested by funds: $16.8M → $4.6M (-$12.2M)

Holders
40
Holders Change
-3
Holders Change %
-6.98%
% of All Funds
0.64%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
2
Increased
5
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
+$111K
2
Renaissance Technologies
Renaissance Technologies
New York
+$91.8K
3
TRCT
Tower Research Capital (TRC)
New York
+$14K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$5.42K
5
BlackRock
BlackRock
New York
+$1.5K

Top Sellers

Rank Fund Capital Flow
1
AI
Aperture Investors
New York
-$322K
2
MP
MSD Partners
New York
-$262K
3
BG
Baupost Group
Massachusetts
-$116K
4
SCM
SCS Capital Management
Massachusetts
-$64K
5
Millennium Management
Millennium Management
New York
-$52.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$850K – – –
AMC
2
Avenir Management Company
New York
$798K – – –
BG
3
Baupost Group
Massachusetts
$489K -$116K -3,470 -9%
Vanguard Group
4
Vanguard Group
Pennsylvania
$487K +$5.42K +162 +0.5%
BL
5
Bleichroeder LP
New York
$389K – – –
LSAG
6
Lake Street Advisors Group
New Hampshire
$355K – – –
TA
7
TRB Advisors
New York
$274K – – –
SW
8
SVB Wealth
Massachusetts
$121K – – –
IC
9
Ikarian Capital
Texas
$114K – – –
OMC
10
Oasis Management Company
Cayman Islands
$108K – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$100K -$535 -16 -0.2%
BCM
12
Bridgeway Capital Management
Texas
$78.8K +$111K +3,334 +156%
MP
13
MSD Partners
New York
$73.6K -$262K -7,843 -61%
BP
14
Ballentine Partners
Massachusetts
$68.9K – – –
Renaissance Technologies
15
Renaissance Technologies
New York
$59K +$91.8K +2,744 +203%
PCP
16
Proficio Capital Partners
Massachusetts
$53.1K – – –
Millennium Management
17
Millennium Management
New York
$36K -$52.2K -1,560 -39%
BlackRock
18
BlackRock
New York
$34.5K +$1.5K +45 +2%
LCM
19
Laurion Capital Management
New York
$27.8K – – –
Northern Trust
20
Northern Trust
Illinois
$12.1K – – –
State Street
21
State Street
Massachusetts
$11.8K – – –
BFM
22
Boothbay Fund Management
New York
$11.5K – – –
Charles Schwab
23
Charles Schwab
California
$9.02K – – –
Goldman Sachs
24
Goldman Sachs
New York
$8.22K -$9.56K -286 -33%
AA
25
Ancora Advisors
Ohio
$8K – – –
1
2

FNCH Hedge Fund Activity: Q4 2022 in Review

40 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q4 2022, worth a combined $4.6M — down 73% from $16.8M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of FNCH and 2 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 5 added.

The largest buyer was Bridgeway Capital Management, adding an estimated $111K. The largest seller was Aperture Investors, exiting entirely with an estimated $322K sold.

  • 40 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q4 2022, down from 43 in Q3 2022.
  • Funds reported $4.6M of Finch Therapeutics Group, Inc. Common Stock stock for Q4 2022, down 73% quarter-over-quarter.
  • 2 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q4 2022 and 5 closed out, a net change of -3 holders.
  • The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q4 2022 was Bridgeway Capital Management, an estimated $111K added.
  • The largest Finch Therapeutics Group, Inc. Common Stock seller in Q4 2022 was Aperture Investors, an estimated $322K sold.

Based on aggregated 13F filings for Q4 2022.